EUVIMEDOpdag EUVIMED
Crossref

Blocking of IL‐4/IL‐13 Signalling With Dupilumab Results in Restoration of Serum and Cutaneous Abnormalities in Netherton Syndrome

Stefan Blunder iD, Natascha Hermann-Kleiter iD, Rita Mahmuti, Martin Hermann iD, Daniela Ortner, Daniela Reider, Verena Moosbrugger-Martinz, Barbara Del Frari iD, Patrizia Stoitzner iD, Sandrine Dubrac iD, Matthias Schmuth iD, Robert Gruber iD

Experimental Dermatology · 2025

DOI: 10.1111/exd.70113 ↗

At a glance

Journal article in Experimental Dermatology, 2025. Written by Stefan Blunder and 11 co-authors. Institution: Department of Dermatology, Venereology and Allergy, Medical University of Innsbruck, Innsbruck, Austria. Major MEDLINE topics: Netherton Syndrome, Antibodies, Monoclonal, Humanized, Interleukin-13, Interleukin-4. Cited 11 times so far (Crossref); 76 references. Funded by: clinician scientist research fellowship grant from the Austrian Society for Dermatology and Venereology (ÖGDV), Medical Research fund Tyrol (MFF).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Netherton syndrome (NS) is a rare ichthyosis caused by SPINK5‐ null mutations, resulting in erythroderma, ichthyosis linearis circumflexa, and atopic diathesis. Elevated serum IgE levels and activation of the KLK5‐PAR2‐TSLP axis suggest involvement of Th2‐skewed immunity in NS. In this pilot study, we investigated the effects of IL‐4/IL‐13 blocking with dupilumab on NS features. At baseline, Th2‐chemokines CCL11, CCL17, CCL18, CCL26, and serum IgE were more elevated in atopic dermatitis (AD) than in NS vs. controls (ctrls). AD exhibited elevated serum levels of CCL27, LDH, and eosinophils, while NS showed higher levels of IL‐9 and IL‐18. Epidermal aberrations, including acanthosis and SC‐detachment, were present in NS versus ctrls. The number of CD3+ T cells increased, while CD1a + Langerhans cell numbers decreased in NS skin. Amounts of KLK5 were reduced, and the distribution of KLK7 was abnormal in NS epidermis as compared to ctrls. Reduced amounts of FLG, CDSN, and DSG1 highlight impaired keratinocyte late differentiation in NS. Amounts of epidermal TSLP were diminished. Upon dupilumab treatment, clinical improvement in NS began as early as week 8 and continued up to 30 months, with no serious side effects reported. Serum levels of IgE, CCL17, CCL26, IFN‐γ and IL‐18 decreased upon IL‐4/IL‐13 blockade, and alterations of cutaneous immune cells improved in NS. Furthermore, the epidermal protease inhibitor WFDC12 expression increased after dupilumab treatment, concurring with improved and partially normalised epidermal structure, including increased FLG, CDSN, and DSG1. These data highlight Th2‐skewed immunity in NS and emphasise the amelioration of NS features through dupilumab treatment.

Subjects

MeSH terms (MEDLINE)

Netherton SyndromeAntibodies, Monoclonal, HumanizedInterleukin-13Interleukin-4HumansMaleDermatitis, AtopicFemaleSerine Peptidase Inhibitor Kazal-Type 5Pilot ProjectsImmunoglobulin EAdultSignal TransductionFilaggrin ProteinsKallikreinsChildAdolescentYoung AdultChild, Preschool

Author keywords

IL‐4/IL‐13 blockadeNetherton syndromedupilumabepidermal differentiationichthyosis

Substances

Antibodies, Monoclonal, HumanizedInterleukin-13dupilumabInterleukin-4SPINK5 protein, humanSerine Peptidase Inhibitor Kazal-Type 5IL4 protein, humanImmunoglobulin EFilaggrin ProteinsKallikreins

Authors and institutions

  • Department of Dermatology, Venereology and Allergy, Medical University of Innsbruck, Innsbruck, Austria.
  • Institute of Cell Genetics, Department for Genetics and Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.
  • Department of Anaesthesiology and Critical Care Medicine, Medical University of Innsbruck, Innsbruck, Austria.
  • Departmtent of Plastic, Reconstructive and Aesthetic Surgery, Medical University of Innsbruck, Innsbruck, Austria.

ORCID profiles: Stefan Blunder, Natascha Hermann-Kleiter, Martin Hermann, Barbara Del Frari, Patrizia Stoitzner, Sandrine Dubrac, Matthias Schmuth, Robert Gruber

Funding

  • clinician scientist research fellowship grant from the Austrian Society for Dermatology and Venereology (ÖGDV)
  • Medical Research fund Tyrol (MFF)

Cite

APA

Blunder, S., Hermann-Kleiter, N., Mahmuti, R., Hermann, M., Ortner, D., Reider, D., Moosbrugger-Martinz, V., Del Frari, B., Stoitzner, P., Dubrac, S., Schmuth, M., & Gruber, R. (2025). Blocking of IL‐4/IL‐13 Signalling With Dupilumab Results in Restoration of Serum and Cutaneous Abnormalities in Netherton Syndrome. Experimental Dermatology. https://doi.org/10.1111/exd.70113

Vancouver

Blunder S, Hermann-Kleiter N, Mahmuti R, Hermann M, Ortner D, Reider D, et al. Blocking of IL‐4/IL‐13 Signalling With Dupilumab Results in Restoration of Serum and Cutaneous Abnormalities in Netherton Syndrome. Experimental Dermatology. 2025. doi:10.1111/exd.70113

BibTeX
@article{Blunder2025,
  author = {Blunder, Stefan and Hermann-Kleiter, Natascha and Mahmuti, Rita and Hermann, Martin and Ortner, Daniela and Reider, Daniela and Moosbrugger-Martinz, Verena and Del Frari, Barbara and Stoitzner, Patrizia and Dubrac, Sandrine and Schmuth, Matthias and Gruber, Robert},
  title = {Blocking of IL‐4/IL‐13 Signalling With Dupilumab Results in Restoration of Serum and Cutaneous Abnormalities in Netherton Syndrome},
  journal = {Experimental Dermatology},
  year = {2025},
  doi = {10.1111/exd.70113}
}
Start for free →